Delivery Order SPE2DB22D9112-SPE2DB25FTKLX

Award Date 4/29/25
Potential Completion Date 5/20/25
Potential Value $8.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $8,220.68, is for the delivery of 4,568,138,974 units of STELARA 90 MG/ML syringes. The contract has an ultimate completion date of May 13, 2025 and was awarded on April 22, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $8,220.68, is for the delivery of 4,567,967,728 units of STELARA 90 MG/ML SYRINGEML, a prescription medication. The contract has an ultimate completion date of May 1, 2025. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler based in Park Ridge, Illinois, that specializes in providing a range of pharmaceutical...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has a ceiling value of $8,220.68 and covers the delivery of STELARA 90 MG/ML SYRINGEML through April 15, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a range of branded and generic prescription drugs, over-the-counter medications,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,220.68 contract is for the delivery of STELARA 90 MG/ML SYRINGE with a period of performance through March 20, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML pharmaceutical products. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a wide range of pharmaceutical...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a completion date of April 25, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a performance period ending on April 22, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $41,103.40 firm fixed-price contract is for the delivery of 4568140127 STELARA 90 MG/ML SYRINGEML, a prescription medication, with a period of performance through May 21, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $32,882.72 and an ultimate completion date of April 8, 2025. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,220.68 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized medication, with a performance period through March 31, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
  • SPE2DB22D9112
    Indefinite Delivery Contract
  • SPE2DB22D9112-SPE2DB25FTKLX
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $8,220.68, is for the delivery of 4,568,138,980 units of STELARA 90 MG/ML SYRINGEML, a prescription medication. The contract has a completion date of May 20, 2025.

DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.

Generated 8/3/25, 1:35 AM